Hazardous medicines have the potential to cause harm via occupational exposure. We describe the development of a guideline to clarify the risks of occupational handling of non-cytotoxic hazardous medicines, and provide practical advice for frontline staff in the hospital setting. Nurses and pharmacists in Victorian hospitals were surveyed to capture their experience, whilst a literature review located 14 national or jurisdictional guidance documents. Nurses and pharmacists reported variance in practices when handling an example medicine (mycophenolate). Many found existing guidance around hazardous non-cytotoxic medicines unclear or confusing. Medicines were categorised into four groups: cytotoxic medicines; hazardous non-cytotoxic medicines; medicines that primarily pose a risk to men and women actively trying to conceive and women who are pregnant or breastfeeding; and medicines that are irritants to mucous membranes or airways. An institutional guideline was developed, with recommendations synthesised into a single-page chart for quick reference at the point of care.
INTRODUCTION
Hazardous medicines are those with the potential to cause harm, via occupational exposure, to healthcare workers and carers. A subset of these medicines are cytotoxic chemotherapy agents used in the treatment of malignancy. The safety precautions required for handling cytotoxic chemotherapy in the oncology setting have been well described in the literature. 1 There is very limited information about the safe handling of non-cytotoxic agents that may be considered hazardous; where they exist, current recommendations are often extrapolated from guidelines created for the cancer chemotherapy setting. A letter to the Journal of Pharmacy Practice and Research in 2005 described the lack of Australian guidance on the handling of hazardous, non-cytotoxic agents. 2 Since then, other papers have described issues around workplace safety and privacy (e.g. staff needing to disclose early pregnancy or that they are trying to conceive). [3] [4] [5] The absence of practical guidance remains an issue. In the US, the National Institute for Occupational Safety and Health (NIOSH; a division of the Centers for Disease Control and Prevention) maintains the List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. 6 The US Pharmacopoeia has revised its guidance on hazardous medicines, with the chapter Hazardous Drugs Handling in Healthcare Settings 7 published in 2016 and expected to become official in December 2019. The standard requires health services to perform a risk assessment for each medicine and dose form in use. 8 Hazardous non-cytotoxic medicines are used for diverse indications, from psoriasis to prevention of transplant rejection. A point-prevalence study at a New South Wales (NSW) tertiary hospital found that 60% of inpatients were prescribed medicine/s that could be considered 'hazardous'. 9 Hospital pharmacists frequently receive enquiries from nursing staff about occupational handling of hazardous medicines. 10 Often the medicine of concern is being used for a condition unrelated to the reason for admission. The extent of exposure to hazardous agents is variable, with the dose form (intact tablet, liquid, injectable) and administration method (including any need for reconstitution) contributing factors. 6 In our practice, within the Australian inpatient hospital setting, pharmacists have seen inconsistencies in the management of patients prescribed hazardous non-cytotoxic medicines. The level of precaution implemented and the inconsistencies between areas has anecdotally caused distress and confusion for patients and their families. Occupational exposure to hazardous, non-cytotoxic medicines can also be an emotive issue for staff, with ramifications for the nursing workforce.
Study Aim
The aim of this study was to provide local institutional guidance with a strong evidence base that is specific to hospital care. We have chosen to approach this issue in two ways: (1) to develop a framework to assess risks with hazardous non-cytotoxic medicines handling in the context of hospital use; and (2) to develop guidance for the handling of hazardous non-cytotoxic medicines.
METHODS
Our work consisted of two parts conducted simultaneously, namely a literature review and a survey of nurses and pharmacists working at Victorian hospitals.
A questionnaire for nurses and pharmacists working in Victorian hospitals was developed and validated by five pharmacists and ten nurses. Institutional ethics approval at Austin Health was obtained; a copy of the questionnaire is provided in Appendix S1, available as Supplementary Material to this paper. The survey was distributed via the VicTAG and SHPA Medicines Information networks. Staff working in oncology were excluded from the study because there are existing guidelines and infrastructure for handling hazardous medicines in this area. In all, 111 staff (nurses and pharmacists) from 10 Victorian health services participated in the survey; 71% of respondents were nurses and staff came from a variety of practice areas (Figure 1 ).
Literature Review
A review of the primary, tertiary and grey literature was conducted to identify a working definition for 'hazardous non-cytotoxic medicines' and existing recommendations for the handling of hazardous non-cytotoxic medicines in non-oncology inpatient settings for commonly used medicines. The collated information was assessed to determine: (1) where specific lists of medicines recommended handling precautions, whether there was concordance between the lists, the nature of the handling precautions recommended and the supporting evidence provided; and (2) where specific criteria for exposure risk stratification are suggested, whether there was concordance between the lists. A complete systematic literature search was not conducted because it became apparent from the initial search that there is a small number of recent, highly regarded national and international guidelines available [6] [7] [8] [9] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] that were repeatedly cited in the papers located.
Monoclonal antibodies are a group of drugs increasingly used for non-cancer indications. The Western and Central Melbourne Integrated Cancer Service developed consensus guidelines in 2014; 11 this group of medicines was excluded from our review. Other specific exclusions were oral cytotoxic medicines (except for low-dose methotrexate for autoimmune conditions), parenteral cytotoxic chemotherapy, hazardous medicines used during medical procedures (e.g. intravesical mitomycin C or intravitreal aflibercept), viral vectors and genetically modified materials being used as therapeutics.
RESULTS

Staff Survey Findings
Analysis of survey responses revealed that: 46% of pharmacists and 33% of nurses reported handling hazardous medicines at least once a week; 52% of respondents would wear gloves to handle intact oral mycophenolate, whereas 22% would not use any special equipment; and 80% of respondents would wear gloves to prepare and administer mycophenolate via a nasogastric tube, 35% would also wear another form of personal protective equipment (PPE) (e.g. eye or face protection) and 8% would not use any special equipment. Opinions were evenly divided around the precautions needed for body waste handling following oral or intravenous mycophenolate administration: 52% of respondents nominated standard precautions, whereas 48% would use 'cytotoxic' precautions. Finally, 67% of staff reported that they had found variations in practice between areas and 66% acknowledged that, overall, the existing guidance is unclear or confusing.
Literature Review Findings
All guidance documents located made reference to the NIOSH guidelines. 6 The NIOSH guidelines were updated in 2016 to a new format that takes a two-tiered approach to risk assessment: (1) pharmacological properties of the compound (e.g. inherent teratogenicity or genotoxicity); and (2) the type of exposure (e.g. administering intact film-coated tablets vs preparing a parenteral product). Earlier versions of the NIOSH guidelines did not make this distinction, treating medicines as either 'hazardous' or 'not hazardous' regardless of the type of exposure. Some jurisdictions found this advice impractical and conducted their own risk assessments.
Quantification of risk is complicated by the frequency of exposure to a hazardous product. We did not locate any guidance around 'safe' levels of exposure relating to frequency.
Many jurisdictional guidelines do not include a list of medicines that should be considered hazardous. Rather, they adopt the NIOSH recommendations. 6 Notably, the 
DISCUSSION
We have chosen to predominantly adopt the NIOSH 2016 definitions of hazardous medicines because these are the most recent, they are comprehensive in nature and they are frequently cited by other leaders in the field.
The current NIOSH approach involves three groups of drugs: NIOSH Group 1, antineoplastic drugs; NIOSH Group 2, non-antineoplastic drugs that meet one or more of the NIOSH criteria for a hazardous drug (i.e. carcinogenicity, teratogenicity or other developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity and structure and toxicity profiles of new drugs that mimic existing drugs determined hazardous by the above criteria); NIOSH Group 3, drugs that primarily pose a reproductive risk to men and women who are actively trying to conceive and women who are pregnant or breastfeeding (because some of these drugs may be present in breast milk).
For the purposes of the guideline, a distinction is made between the terms 'antineoplastic' and 'cytotoxic' using the definitions from the NSW eviQ group. 17 Specifically, an antineoplastic (anti-cancer) drug is an agent used to control or kill cancer cells and includes cytotoxic, hormonal, immune system-modifying, some antiviral, biological and molecular-targeted therapies, whereas a cytotoxic drug is an agent capable of disrupting the growth and function of both healthy and diseased cells, and can be carcinogenic, genotoxic, mutagenic, teratogenic or in any way hazardous to cells.
The use of low-dose methotrexate to treat autoimmune conditions (oral or parenteral) outside the oncology setting was a particular focus of our search. Methotrexate straddles a divide, whereby this unique drug can be administered at vastly different doses and for different indications. This gives great variance in expected theoretical occupational exposure within and outside the oncology setting.
Data Collation in the Local Context
Medicines have been grouped by comparing the recommendations; the key guidelines were often in concordance. Where there were differences, the risks were examined in closer detail, other references were consulted and a consensus was made by the review group. Medicines were categorised into four groups: Group A, cytotoxic medicines; Group B, hazardous non-cytotoxic medicines; Group C, medicines that primarily pose a risk to men and women actively trying to conceive and women who are pregnant or breastfeeding; and Group D, medicines that are irritant to mucous membranes or airways (Figure 2) .
Once the list of hazardous non-cytotoxic medicines was developed, recommendations for safe handling from the national and jurisdictional guidelines [6] [7] [8] [9] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] were appraised. Many of the recommendations were consistent and similar to existing practice. However, most guidelines specifically prohibit crushing or modifying solid-dose forms on the ward.
We have considered the practicalities of designating a medicine as hazardous in the clinical inpatient context in which some medicines are commonly used (e.g. depot antipsychotics, angiotensin-converting enzyme (ACE) inhibitors). We have also considered medicines that are known to be irritants to mucous membranes and airways, because these are also occupational exposure risks.
ACE inhibitors (e.g. perindopril), angiotensin II receptor antagonists (e.g. irbesartan), statins (e.g. atorvastatin) and sodium-glucose cotransporter 2 inhibitors (e.g. dapagliflozin, empagliflozin) are not included in all lists of hazardous medicines. A comment was added to the guideline to explain this anomaly and to suggest that staff 'may wish to use handling precautions for these medicines'.
We are aware that across many clinical specialties, medicines commonly need to be modified (e.g. neurology, psychiatry). The stringent handling precautions proposed in some guidelines (e.g. the APF 14 Occupational handling of hazardous medicines
Consensus Recommendations
A list of hazardous non-cytotoxic medicines is given in Table 1 .
Recommendations for the Safe Handling of Hazardous Non-cytotoxic Medicines
The risk of occupational exposure from hazardous medicines is difficult to quantify but is dependent on the medicine, the frequency of exposure, the route of exposure and how the medicine is being handled (e.g. administering an intact film-coated tablet orally is different to crushing a medicine for administration via a nasogastric tube). Wherever possible, the risk of exposure to hazardous medicines should be eliminated (e.g. the 'no touch' technique for dispensing a tablet from a bottle). In addition, workplace tasks may be reallocated to entirely avoid potential exposures to staff who are pregnant, breastfeeding or trying to conceive. If this is not possible, PPE is recommended as per Table 2 . The type of PPE required depends on the likelihood of exposure to a body area. Medicines considered 'hazardous' (including cytotoxic medicines) should come with instructive written warnings. The wording of Label 21 of the APF 14 ('special handling is required -ask your pharmacist') may be appropriate for patients in the community, but has been a source of confusion in the inpatient setting. We recommend instructive warnings similar to those used The wording of warning labels should be consistent across all interfaces, including dispensing software and container labels used for inpatient dispensing, medication administration records (paper and electronic) and hospital guidelines.
Intravenous line labels for continuous infusions of hazardous medicines could be considered. Note that these are not included in the National Standard for UserApplied Labelling of Injectable Medicines, Fluids and Lines. 23 Body waste handling is a common source of confusion. Guidelines describing cytotoxic handling and infection control procedures mandate the use of PPE whenever there is a risk of exposure to body fluids, regardless of when the last dose of a hazardous medicine was taken. 24 For some medicines, standard nursing precautions (i.e. those used to achieve a basic level of infection control when handling body waste) may be sufficient. It is our experience that the protection provided by routine good practice use of PPE by nursing staff according to Australian guidelines 24 (gloves with or without a gown, goggles etc.) is on occasion not taken into account by enquirers to the Medicines Information Service. This baseline protection from body waste exposure is particularly relevant for oral medicines taken for indications other than immunosuppression or chemotherapy (e.g. oestrogens, carbamazepine, risperidone). For these agents, it may not (to date) be obvious that precautions could be prudent. Our guideline document makes specific reference to 'low-dose' methotrexate for autoimmune conditions. Where methotrexate is given at a low dose once weekly (orally or parenterally), some general principles have been applied. 25, 26 In this situation, our recommendation is that no special additional precautions are required for the handling of body fluids. Overall, there should be consistency across a health service as to when and where protective measures are recommended for occupational medication handling.
A summary table of hazardous non-cytotoxic medicines in the Australian setting (Table 1) is included in the guideline. For recommendations regarding the use of PPE for handling hazardous medicines, see Table 2 . These documents could be displayed in ward areas for reference.
CONCLUSION
This evidence-based guideline is a practical tool for the safe handling of hazardous non-cytotoxic medications by hospital staff. It was created in response to a need, identified through our Medicines Information Service, and reflects current best practice in the Australian context. It encourages staff to adequately protect themselves, considering risks unique to the person and the particular medicine. It also provides a decision-making framework for new agents in the future. Staff who are pregnant, actively trying to conceive or breastfeeding may wish to use precautions for handling hazardous non-cytotoxic medicines beyond those suggested above, by personal preference. Workplace reallocation of tasks to avoid exposure should be considered in the first instance. General advice to reduce exposure to hazardous non-cytotoxic medicines is as follows. For oral/enteral dose form preparations: (1) do not touch tablets directly (tip into a medicine cup to administer); and (2) refer to current edition of the Australian Don't Rush to Crush Handbook 13 or ask a pharmacist for specific advice (the Australian Don't Rush to Crush Handbook is available via MIMs (on the 'Crush?' tab for each monograph) or as a hardcopy reference). For injectable product preparations: (1) prepare products at waist height (not face height); and (2) consider using a large-gauge needle or an airway needle for drawing up (to reduce the risk of solution spraying; in some circumstances, using a closed system or preparing the medicine within the Pharmacy may be an option).
